CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Subsidiary of CSPC Pharmaceutical Group (1093) · China

Assets

(4 total)
4Total Assets
0Approved
4Phase 3 / Filed
0Phase 1–2 / Early
7Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 3
Microtubules (tubulin)Small molecule
Non-Small Cell Lung CancerBreast Cancer
HER2-Positive Breast Cancer
Phase 3
PD-1Monoclonal antibody
Non-Small Cell Lung CancerCervical Cancer
Phase 3
mTOR (mechanistic target of rapamycin complex 1), via FKBP-12Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 3
IL-4R-alphaMonoclonal antibody
Atopic DermatitisChronic Obstructive Pulmonary DiseaseAsthmaPrurigo Nodularis

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Docetaxel (HB1801)Phase 2Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression
Est. primary completion 2026-12-25 · NCT06525350 · CT.gov ↗
What to watch
2027 (3)
February 2027 (1)
stapokibartPhase 3Atopic Dermatitis
Est. primary completion 2027-02 · NCT07106372 · CT.gov ↗
What to watch
April 2027 (1)
EnlonstobartPhase 1/2Locally Advanced Unresectable Esophageal Squamous Carcinoma
Est. primary completion 2027-04 · NCT06136988 · CT.gov ↗
What to watch
November 2027 (1)
Sirolimus for Injection (Albumin-bound)Phase 2Epithelioid Hemangioendothelioma
Est. primary completion 2027-11-30 · NCT07684287 · CT.gov ↗
What to watch
2028 (2)
June 2028 (2)
Docetaxel (HB1801)Phase 3HER2-Negative Advanced Breast Cancer
Est. primary completion 2028-06-01 · NCT07805135 · CT.gov ↗
What to watch
EnlonstobartPhase 1/2Advanced Hepatocellular Carcinoma (HCC)
Est. primary completion 2028-06-26 · NCT07282509 · CT.gov ↗
What to watch
2032 (2)
April 2032 (1)
stapokibartPhase 2/3Chronic Obstructive Pulmonary Disease
Est. primary completion 2032-04-29 · NCT06547333 · CT.gov ↗
What to watch
May 2032 (1)
stapokibartPhase 2/3Moderate to Severe Asthma
Est. primary completion 2032-05 · NCT05761028 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(8)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

18 August 2026Filing acceptedDocetaxel (HB1801)NMPA accepted the NDA for anbenitamab plus HB1801 in first-line HER2-positive advanced breast cancer, with priority review
CN, NMPA · Source ↗
4 August 2026Filing acceptedDocetaxel (HB1801)NMPA accepts the NDA for anbenitamab (KN026) with docetaxel for injection (albumin-bound) (HB1801) as neoadjuvant therapy, with priority review
CN, NMPA · CSPC Pharmaceutical Group · Source ↗
27 July 2026Filing acceptedSirolimus for Injection (Albumin-Bound) (HB1901)NMPA accepts the HB1901 new drug application, with Priority Review
CN, NMPA · CSPC Pharmaceutical Group · Source ↗
10 June 2026Topline resultHB1801KN026-003 Phase III meets PFS primary endpoint
CSPC Pharmaceutical Group Limited · Source ↗
20 April 2026Topline resultSirolimus for Injection (Albumin-Bound) (HB1901)Pivotal Phase Ib/III HB1901-004 study in advanced malignant PEComa met its primary endpoint
CSPC Pharmaceutical Group · Source ↗
March 2026Filing acceptedstapokibartNMPA accepts stapokibart application in prurigo nodularis
CN, NMPA · Keymed Biosciences · Source ↗
January 2026Filing acceptedstapokibartNMPA accepts stapokibart application in adolescent AD
CN, NMPA · Keymed Biosciences · Source ↗
28 April 2024Topline resultstapokibartPhase III PHECDA (NCT05908032) in seasonal allergic rhinitis met its primary endpoint
Keymed Biosciences Inc. · Source ↗

Financial reports

No financial reports recorded.